Secondly, the development of IGF neutralizing antibodies provides a means of blocking IGF-1R and INSR-A without compromising insulin signaling via INSR-B [201,202], thereby avoiding dose-limiting hyperglycemia that contributed to adverse outcomes in IGF-1R inhibitor trials. This evidence concerns the gene INS and Hyperglycemia.